Open access
Open access
Powered by Google Translator Translator

Covid-19

Consensus Statement: Definition, diagnosis, and management of COVID-19-associated pulmonary mucormycosis.

5 Apr, 2022 | 09:54h | UTC

Definition, diagnosis, and management of COVID-19-associated pulmonary mucormycosis: Delphi consensus statement from the Fungal Infection Study Forum and Academy of Pulmonary Sciences, India – The Lancet Infectious Diseases

 

Perspective: The evidence on 4th doses of covid vaccines & the thorny question of age thresholds.

5 Apr, 2022 | 09:46h | UTC

The Evidence On 4th Doses of Covid Vaccines & the Thorny Question of Age Thresholds – Absolutely Maybe Blog, by Hilda Bastian

Related:

U.S. approves second Covid-19 booster for people 50 and older and immunocompromised individuals.

[Preprint] Retrospective cohort study: second booster vaccine and Covid-19 mortality in adults 60 to 100 years old.

Among health care workers, a fourth dose vaccine effectiveness against any SARS-CoV-2 Omicron variant infection was 30% for the Pfizer–BioNTech and 11% for the Moderna.

[Preprint] Fourth dose of COVID vaccine offers only slight boost against Omicron infection.

Covid-19: Fourth vaccine doses—who needs them and why?

[Not published yet] Study in Israel finds fourth COVID booster has limited efficacy.

 

Commentary on Twitter

https://twitter.com/hildabast/status/1509724907965665280

 

Cohort Study: Change in heart disease and stroke mortality before and during the Covid-19 pandemic.

5 Apr, 2022 | 08:47h | UTC

Age-Adjusted Mortality Rates and Age and Risk–Associated Contributions to Change in Heart Disease and Stroke Mortality, 2011-2019 and 2019-2020 – JAMA Network Open

Commentaries:

Several-Fold Increase in Stroke and Heart Disease Deaths During COVID-19 Pandemic – NeurologyToday

2019 to 2020 Saw Risk-Linked Deaths From Heart Disease, Stroke Up – HealthDay

 

Commentary from the author on Twitter (thread – click for more). Article and images under CC-BY License

 

RCT: Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D).

5 Apr, 2022 | 08:50h | UTC

Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India – The Lancet

Invited Commentary: DNA vaccines join the fight against COVID-19 – The Lancet

 

Commentary on Twitter

 

WHO Strategic preparedness, readiness and response plan to end the global Covid-19 emergency in 2022.

4 Apr, 2022 | 01:44h | UTC

Strategic Preparedness, Readiness and Response Plan to End the Global COVID-19 Emergency in 2022 – World Health Organization

 

Commentary on Twitter (thread – click for more)

 

Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge (deliberately infecting individuals in a controlled environment) in young adults.

4 Apr, 2022 | 01:27h | UTC

Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults – Nature Medicine

Commentaries:

Understanding COVID-19 through human challenge models – Nature Medicine

First human challenge study of Covid-19 yields valuable insights about how we get sick – CNN

First Human Challenge Trial Shows How COVID-19 Strikes – HealthDay

Related:

Scientists deliberately gave people COVID — here’s what they learnt.

[Preprint] Results from the first Covid-19 human challenge study (deliberately infecting individuals in a controlled environment).

Perspective | SARS-CoV-2 human challenge studies — establishing the model during an evolving pandemic.

World’s first coronavirus “Human Challenge” study receives ethics approval in the UK  (several texts on the subject)

Are SARS-CoV-2 Human Challenge Trials Ethical? – “A clinical trial is underway in the UK in which young, healthy participants are exposed deliberately to SARS-CoV-2 to assess the viral inoculum needed to produce an infection and to test vaccine efficacy”.

 

Commentary on Twitter

 

Two new studies show vaccination provides additional protection after Covid-19 infection.

4 Apr, 2022 | 01:16h | UTC

Study 1: Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden – The Lancet Infectious Diseases

Study 2: Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study – The Lancet Infectious Diseases

Commentaries:

Interplay of infection and vaccination in long-term protection from COVID-19 – The Lancet Infectious Diseases

Effectiveness of SARS-CoV-2 vaccines in the post-natural infection world – The Lancet Infectious Diseases

Vaccines offer substantial extra protection after COVID-19 infection – CIDRAP

Had COVID? Getting Vaccine Boosts Resilience Even More, Studies Show – HealthDay

Related:

Retrospective cohort study: Pfizer vaccine reduces the risk of reinfection after recovery from Covid-19.

Cohort study: Protection against SARS-CoV-2 after Covid-19 vaccination lasts longer in patients with previous infection.

 

Commentary on Twitter (thread – click for more)

 

Still coughing after COVID? Here’s why it happens and what to do about it.

1 Apr, 2022 | 09:50h | UTC

Still coughing after COVID? Here’s why it happens and what to do about it – The Conversation

 

Study finds mother-to-child transmission of COVID-19 infection is possible but rare.

1 Apr, 2022 | 09:52h | UTC

News Release: Mother to child transmission of COVID-19 infection, possible but rare, study finds – University of Birmingham

Original Study: SARS-CoV-2 positivity in offspring and timing of mother-to-child transmission: living systematic review and meta-analysis – The BMJ

Editorial: Transmission of SARS-CoV-2 from mother to baby is rare

 

Commentary on Twitter

 

WHO Global genomic surveillance strategy for pathogens with pandemic and epidemic potential 2022–2032.

31 Mar, 2022 | 08:45h | UTC

Global genomic surveillance strategy for pathogens with pandemic and epidemic potential 2022–2032 – World Health Organization

News Release: WHO releases 10-year strategy for genomic surveillance of pathogens – World Health Organization

 

Commentary on Twitter (thread – click for more)

 

RCT: Early treatment with ivermectin does not improve outcomes in patients with Covid-19.

31 Mar, 2022 | 08:41h | UTC

Effect of Early Treatment with Ivermectin among Patients with Covid-19- New England Journal of Medicine

Commentary: Ivermectin does not prevent COVID-19 hospitalization, a new study says – NPR

 

Commentary on Twitter

 

RCT: Early outpatient treatment with convalescent plasma reduces the risk of hospitalization in patients with Covid-19.

31 Mar, 2022 | 08:39h | UTC

Early Outpatient Treatment for Covid-19 with Convalescent Plasma – New England Journal of Medicine

Commentaries:

Study finds convalescent plasma can be effective early COVID-19 therapy – Johns Hopkins University School of Medicine

Early Use of High-Titer Plasma Reduced COVID Hospitalizations— Randomized trial that influenced indication shows benefits in a mostly unvaccinated population – MedPage Today (free registration required)

 

Commentary on Twitter

https://twitter.com/NEJM/status/1509278140433981444

 

Risk of SARS-CoV-2 reinfections in children: a prospective national surveillance study in England.

31 Mar, 2022 | 08:29h | UTC

Risk of SARS-CoV-2 reinfections in children: a prospective national surveillance study between January, 2020, and July, 2021, in England – The Lancet Child & Adolescent Health

Invited Commentary: Importance of understanding the reinfection risk of COVID-19 in children – The Lancet Child & Adolescent Health

 

Commentary on Twitter

 

Case-control study: In children 5 to 11 years of age, the Pfizer vaccine showed an effectiveness of 68% against hospitalization caused by the Omicron variant.

31 Mar, 2022 | 08:37h | UTC

BNT162b2 Protection against the Omicron Variant in Children and Adolescents – New England Journal of Medicine

Commentary: COVID vaccination of children age 5-11 cut omicron hospitalizations by 68% – Children’s Hospital Boston

Related: [Preprint] Study shows significantly reduced effectiveness of the Pfizer vaccine in children 5 to 11 after the emergency of the Omicron variant.

 

Commentary on Twitter

 

[Preprint] Retrospective cohort study: second booster vaccine and Covid-19 mortality in adults 60 to 100 years old.

30 Mar, 2022 | 10:44h | UTC

Second Booster Vaccine and Covid-19 Mortality in Adults 60 to 100 Years Old – Research Square

Commentaries:

Huge Study Finds Second COVID-19 Booster is ‘Life-saving’ for Over 60s – Health Policy Watch

Fourth COVID-19 vaccine dose substantially reduces mortality in the elderly – News Medical

 

Cohort Study: Short-term outcomes of corticosteroid monotherapy in multisystem inflammatory syndrome in children.

30 Mar, 2022 | 10:40h | UTC

Short-term Outcomes of Corticosteroid Monotherapy in Multisystem Inflammatory Syndrome in Children – JAMA Pediatrics

 

Commentary on Twitter

 

U.S. approves second Covid-19 booster for people 50 and older and immunocompromised individuals.

30 Mar, 2022 | 10:42h | UTC

U.S. approves second Covid-19 booster for people 50 and older – STAT

FDA OKs second COVID booster shot for older Americans – CIDRAP

See Guidance: Coronavirus (COVID-19) Update: FDA Authorizes Second Booster Dose of Two COVID-19 Vaccines for Older and Immunocompromised Individuals – U.S. Food & Drug Administration

 

The RECOVERY Trial – two years on.

30 Mar, 2022 | 10:38h | UTC

The RECOVERY Trial – two years on – University of Oxford

Related:

How the UK found the first effective Covid-19 treatment — and saved a million lives (about the RECOVERY trial and the effects of Dexamethasone)

Covid: The London bus trip that saved maybe a million lives (about the creation of the RECOVERY Trial)

Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19 – Recovery Trial

[Preprint] RECOVERY trial shows Baricitinib reduces deaths in patients hospitalized with COVID-19.

RCT: CPAP improved outcomes in patients with acute hypoxemic respiratory failure due to COVID-19, but high-flow nasal oxygen was not better than conventional oxygen therapy.

RECOVERY Trial: In patients admitted to hospital with COVID-19, Colchicine did not reduce 28-day mortality, duration of hospital stay, or risk of progressing to invasive mechanical ventilation or death.

RECOVERY Trial: No benefit from convalescent plasma in patients admitted to hospital with COVID-19.

RECOVERY Trial: Aspirin as an add-on therapy did not reduce mortality in patients hospitalized with COVID-19.

RECOVERY trial: In hospitalized COVID-19 patients with hypoxia and systemic inflammation (C-reactive protein ≥75 mg/L), tocilizumab improved survival and other clinical outcomes

RECOVERY trial: Azithromycin not beneficial for patients admitted to hospital with COVID-19

[Preprint] RECOVERY trial finds Regeneron’s monoclonal antibody combination reduces deaths for hospitalized COVID-19 patients who have not mounted their own immune response.

RECOVERY trial: Effect of hydroxychloroquine in hospitalized patients with Covid-19

Randomized trial: Lopinavir–ritonavir not beneficial for patients admitted to hospital with COVID-19

 

Commentary on Twitter

https://twitter.com/MartinLandray/status/1508492188560371717

 

M-A: Parenchymal lung abnormalities following hospitalization for COVID-19 and viral pneumonitis.

30 Mar, 2022 | 10:26h | UTC

Parenchymal lung abnormalities following hospitalisation for COVID-19 and viral pneumonitis: a systematic review and meta-analysis – Thorax

 

Opinion: Global vaccination must be swifter.

29 Mar, 2022 | 10:12h | UTC

Global vaccination must be swifter – Nature

 

Myocarditis and pericarditis after COVID-19 vaccination: clinical management guidance for healthcare professionals.

29 Mar, 2022 | 10:09h | UTC

Myocarditis and pericarditis after COVID-19 vaccination: clinical management guidance for healthcare professionals – UK Health Security Agency

Related:

Myocarditis following a third Pfizer vaccination dose in military recruits in Israel.

Myocarditis following COVID-19 BNT162b2 vaccination among adolescents in Hong Kong.

[Preprint] Post-marketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12-39 years in Italy.

Myocarditis after BNT162b2 vaccination in Israeli adolescents.

Myocarditis cases reported after mRNA-Based COVID-19 vaccination in the US from December 2020 to August 2021.

A case-control study showed an increased risk of myocarditis after COVID-19 vaccination with a messenger RNA vaccine compared to an inactivated virus vaccine.

[Preprint] Risk of myocarditis following sequential COVID-19 vaccinations by age and sex.

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination vs. SARS-CoV-2 infection.

Case series with 139 adolescents and young adults with suspected myocarditis following mRNA vaccination showed most cases had a mild clinical course and rapid resolution of symptoms.

Heart-inflammation risk from Pfizer COVID vaccine is very low.

Large cohort study with over 2.5 million individuals showed the incidence of myocarditis after the Pfizer vaccine was 2.13 cases per 100,000 persons.

Study with over 5.1 million vaccinated individuals showed the incidence of myocarditis after the receipt of the Pfizer vaccine was low and more common after the second dose in young male recipients.

Large Observational study shows Pfizer Covid vaccine is mostly safe but is associated with increased risk of myocarditis, adenopathy, appendicitis, and herpes zoster.

 

Brazilian guidelines for the treatment of outpatients with suspected or confirmed COVID-19.

29 Mar, 2022 | 10:05h | UTC

Brazilian guidelines for the treatment of outpatients with suspected or confirmed COVID-19. A joint guideline of the Brazilian Association of Emergency Medicine (ABRAMEDE), Brazilian Medical Association (AMB), Brazilian Society of Angiology and Vascular Surgery (SBACV), Brazilian Society of Geriatrics and Gerontology (SBGG), Brazilian Society of Infectious Diseases (SBI), Brazilian Society of Family and Community Medicine (SBFMC), and Brazilian Thoracic Society (SBPT) – The Brazilian Journal of Infectious Diseases

 

Moderna to ask FDA to authorize Covid-19 vaccine in children 6 months to 6 years.

28 Mar, 2022 | 10:01h | UTC

Moderna to ask FDA to authorize Covid-19 vaccine in children 6 months to 6 years – STAT

 

Riding the Twitter wave: Enthusiasm for the social media platform changed science communication during the pandemic—but will it last?

28 Mar, 2022 | 09:56h | UTC

Riding the Twitter wave: Enthusiasm for the social media platform changed science communication during the pandemic—but will it last? – Science

Related:

Optimizing the use of Twitter for research dissemination: The “Three Facts and a Story” randomized-controlled trial.

Perspective: How Twitter is Changing Medical Research

Keeping Up With Cardiology: Old-School Learning Versus the Twittersphere – TCTMD

Scientists on Twitter: Preaching to the choir or singing from the rooftops? – Facets

Rise of the Tweetorial – Precious Bodily Fluids

Social Medicine: Twitter in Healthcare – Journal of Clinical Medicine

University of Twitter? Scientists give impromptu lecture critiquing nutrition research – CBC

Twitter-Based Medicine: How Social Media is Changing the Public’s View of Medicine – The Health Care Blog

What’s your doctor reading? How social media is disrupting medical education – National Post

 

Commentary on Twitter

https://twitter.com/onisillos/status/1507398283416768515

 

Cohort Study: SARS-CoV-2 co-infection with influenza viruses, respiratory syncytial virus, or adenoviruses is associated with increased mortality.

28 Mar, 2022 | 10:03h | UTC

SARS-CoV-2 co-infection with influenza viruses, respiratory syncytial virus, or adenoviruses – The Lancet

Commentary: Patients with Covid and flu double the risk of dying, say scientists – The Guardian

 

Commentary from the author on Twitter (thread – click for more)

https://twitter.com/kennethbaillie/status/1507501279181955076

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.